Login
Boehringer Ingelheim
  • Therapeutic Area
    • Metabolic
  • Resources
  • Contact
Login

simple. every. day
 
 

Are your T2D patients on the right DPP4i dose?

 

04/03/2020

Author: Boehringer Ingelheim

Related content

DPP4i - Proven efficacy with no dose reduction

00:38

DPP4i - Proven efficacy with no dose reduction
DPP4i – What efficacy to expect?

00:27

DPP4i – What efficacy to expect?
Efficacy, Safety, Simplicity all in one DPP4i

00:54

Efficacy, Safety, Simplicity all in one DPP4i
JENTADUETO® dosing information

01:22

JENTADUETO® dosing information
Renally impaired patients - Are they on the right dose?

00:38

Renally impaired patients - Are they on the right dose?
Restricting TRAJENTA® to only renally impaired patients

00:21

Restricting TRAJENTA® to only renally impaired patients
Production date: March 2020
Close ×
  • Therapeutic Area
  • Metabolic
  • Resources
  • Videos
  • Clinical studies
  • Site map
  • Terms of use
  • Privacy
  • Contact
  • Change country

© 2010-2025
Boehringer Ingelheim International GmbH.
All rights reserved.